Physician profile
James A Darrow
NPI 1023013042
$1,402.51
in general payments reported to CMS, 2019-2025
12 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $104 · 2021: $194 · 2022: $192 · 2023: $30.46 · 2024: $185 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $655.25 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $204.01 | 2019-2021 | |
| Abbvie INC. | $180.43 | 2021-2025 | |
| Amgen INC. | $103.90 | 2022 | |
| Pfizer INC. | $78.03 | 2019-2021 | |
| Allergan, INC. | $69.58 | 2020 | |
| Sanofi Pasteur INC. | $24.55 | 2024 | |
| Esperion Therapeutics, INC. | $20.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.26 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Darrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.